1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMultidisciplinary Machine-Assisted Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey is sponsored by National Center for Advancing Translational Sciences (NCATS) / NIH. NCATS funds innovative research using various tools and approaches to shorten the time it takes to identify and accurately diagnose rare diseases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Multidisciplinary Machine-Assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey | National Center for Advancing Translational Sciences U.S. Department of Health & Human Services National Institutes of Health Multidisciplinary Machine-Assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey We want to find innovative ways to shorten the timeline for getting a correct diagnosis, especially for people with a rare disease.
The Need for New Approaches to Diagnose Rare Diseases More Quickly Eric W. K. Sid, M.
D. , M. H.
A. For people with rare diseases, getting a correct diagnosis can take years and many visits to different doctors. During this “diagnostic odyssey,” people with rare diseases might have unnecessary tests and procedures, receive the wrong diagnosis, and experience delays in getting effective care.
This long timeline means that many people with rare diseases experience irreversible damage as the disease progresses. Some may miss when interventions could be the most helpful. We have awarded funding to support three research projects that will study new tools and approaches to make it easier to correctly diagnose people with rare diseases.
Each of the three projects is exploring a different approach to speed up the timeline for a correct diagnosis. These approaches include machine learning, genetic analyses and medical evaluation. To be successful, the approaches must be easy to apply and used early in patient care by front-line health care providers.
Funding for the awards comes in two phases. Research teams must meet goals in the first phase before they move on to the next. In the first phase, researchers must create a strategy for using their proposed approach to make faster diagnoses and test that strategy in a real-world setting.
In the second phase, researchers will test their strategy with patients in a different health care setting that presents new challenges or obstacles. Find past and current awards for this initiative via the NIH Research Portfolio Online Reporting Tools Expenditures and Results ( RePORTER ). Last updated on July 15, 2025
According to the current listing, eligibility includes: Not specified, but generally targets research institutions. Confirm the full requirements in the official notice before applying.
Multidisciplinary Machine-Assisted Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey is funded by National Center for Advancing Translational Sciences (NCATS) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articlePAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read article